基因测序公司Illumina(ILMN)周四盘后大跌近6%,引发市场关注。主要原因是公司当天下调了2024年收入指引,预计2024年核心Illumina收入与2023财年相比将下降约3%,低于之前的乐观展望。公司将此归咎于近期宏观经济环境受限。
此外,Illumina也下调了第四季度收入指引,预计为10.7亿美元,低于分析师预测的11.5亿美元。投资者对上述指引不佳反应消极,纷纷抛售Illumina股票,导致盘后交易中股价大跌5.73%,报338.7美元。
不过Illumina还有一些积极信号,包括第三季度业绩超预期,以及上调了2024年全年调整后每股收益指引至4.05-4.15美元区间,高于之前3.91美元预期。不过投资者对收入指引的关注显然更大。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.